Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute Lymphoblastic Leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  Next»
    Study title: Children's Cancer Group Study CCG-1961 : Asparaginase antibodies and asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21882
    Study title: Comparison of chemotherapy dose modifications in obese and nonobese pediatric patients with acute lymphoblastic leukemia (ALL).
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21961
    Study title: DCLSG ALL-8 study: BFM-oriented treatement for children with acute lymphoblastic leukemia without cranial irradiation and treatement reduction for standard risk patients
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21964
    Study title: DFCI ALL 81-01 study : Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21890
    Study title: DFCI ALL 85-01 study: Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21891
    Study title: DFCI ALL 87-01 study : Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21892
    Study title: DFCI ALL 91-01 study : Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21893
    Study title: DFCI ALL 95-01: Protocols for children with newly diagnosed acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21920
    Study title: Multicenter trial for treatment of acute lymphoblastic leukemia in adults (05/93)
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21934
    Study title: PARKAA study : A Prospective Cohort Study Determining the Prevalence of Thrombotic Events in Children with Acute Lymphoblastic Leukemia and a Central Venous Line Who are Treated with L-Asparaginase
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21901
    Study title: POG 9006 study : A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21926
    Study title: A study of children with refractory or relapsed acute lymphoblastic leukemia (ALLR16)
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21931
    Study title: Acute lymphoblastic leukemia in children : non randomized comparison of conventional vs intensive chemotherapy at the national cancer institute of Colombia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21947
    Study title: AIEOP ALL 91 Study : Effect of protracted high-dose L-asparaginase given as a second exposure in a BFM based treatement ; results of the randomised 9102 intermediate-risk chodhood acute lymphoblastic leukemia study
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21897
    Study title: AIEOP ALL 91 Study : Effect of protracted high-dose L-asparaginase given as a second exposure in a BFM based treatement ; results of the randomised 9102 intermediate-risk chodhood acute lymphoblastic leukemia study
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21938
    Study title: Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relatioship to outcome : a case-control study
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21962
    Study title: CCG-1952 study for standard -risk acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21929
    Study title: CCG-1952 study for standard -risk acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21948
    Study title: CCG-1961 study : ASP antibodies and asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21950
    Study title: Children 's Cancer group 1952 study for standard -risk acute lymphoblastic leukemia
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21965
    1  2  3  4  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 08:32:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA